A trial on Plasma-based therapeutic in patients with mild to moderate Alzheimer's Disease (AD)
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs GRF-6019 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms PLASMA
- Sponsors Alkahest
- 08 Nov 2017 New trial record
- 01 Nov 2017 Results presnted in an Alkahest Media Release.
- 01 Nov 2017 According to an Alkahest media release, Nine subjects were enrolled randomized and treated under the double-blind crossover protocol, and an additional nine subjects were enrolled and treated under an open-label amendment.